急性肠系膜动脉缺血是一种发生率较低的血管科急腹症.这一类疾病包括肠系膜上动脉血栓形成、栓塞及痉挛等不同病理生理机制导致的突发性肠系膜动脉血流受阻.急性肠系膜动脉缺血病死率较高,原因是在急腹症的鉴别诊断中对其认识不足,导致确诊和治疗的延误.急性肠系膜动脉缺血的病人必须及时诊断并即刻开始治疗,治疗手段包括药物复苏及治疗、血管腔内治疗和外科血管重建及坏死肠管切除.积极有效的药物治疗是改善预后的关键,也是整个治疗过程的基础,必须加以重视.

Objective:The arm of trial is to study to treat serious lower extremity ischemia by low molecule weight heparin(LMWH)cooperated with sarpogrelate.Methods: We conducted a randomized cohort trial,in which 43 patients(experimental group) were assigned to apply LMWH cooperated with sarpogrelate,40 patients(compared group) were assigned to apply cilostazol cooperated with pancreatic kallikrein.To compare their validity and security between 2 groups.Results: The excellent,productive and invalid ratio of the experimental group are respectively 38.5%(30/78),48.7%(38/78)and 12.8%(10/78).Them of the compared group are respectively 10.1%(7/69),14.5%(10/69)and 75.4%(52/69)(P0.001).There is none of bleeding in two groups.Conclusion: LMWH cooperated with sarpogrelate plays a big role in increasing distance of claudication in FontaineⅡ,eliminating or alleviating rest pain in Fontaine Ⅲ or Ⅳ,promoting to form lateral branch artery,and no in increasing blooding.These give expression to validity and security in treatment of LMWH cooperated with sarpogrelate.